Message from CEO

      As the Chinese society develops with breakneck speed, the people have higher and higher expectations on their health and wellbeing. However, China’s healthcare system in general still lags behind the world’s best. In the field of ophthalmology, the deficiencies in treatment options are particularly conspicuous. For the society as a whole, there is an urgent need for a platform to integrate social resources to provide Chinese ophthalmic patients access to the best drugs and devices in the world to address their unmet medical needs.

     And so it is, Ocumension Therapeutics was born.

      Leveraging the combination of powerful capital and excellent talent, through a deep understanding of the medical needs in the ophthalmic domain, and using a global network, Ocumension Therapeutics has become a R&D-driven enterprise in China ophthalmology par excellence. Its current pipeline has covered almost all ophthalmic indications, including uveitis, glaucoma, wet age-related macular degeneration, allergies, blepharitis, dry eye and various infections, and its products have notable potential advantages in these areas. These products include those licensed in from advanced countries, and those developed by its own research and development team. Based on this pipeline, Ocumension Therapeutics has quickly grown into an ophthalmic platform company that provides excellent and comprehensive treatment solutions for the Chinese patients and medical community.

      In the years to come, Ocumension Therapeutics will continue to endeavor to not only develop good products, but also produce good products with high quality and, through its own commercialization network, deliver these high-quality, good products to patients, to relieve their pain, and to redeem its own value through service to society.

      Give Ocumension Therapeutics this great era, and give this great era to Ocumension Therapeutics.

Ocumension Therapeutics

Chief Executive Officer